预防血栓形成的方法过去主要是阻碍血凝,静脉血栓通常开始于瓣窦,因此处血流相对滞缓。肝素和香豆素能防止此型血栓形成,但对动脉血栓形成则无效。血小板凝集可能是引起动脉血栓形成和人工装置表面血栓形成的更为重要的因素。实验和临床资料日益证明,应用抗血小板凝集药物是一种新的防止血栓形成的药理学途径。血小板易粘附于血管壁内膜脱失后暴露出来的某些成分,继而发生释放反应,释出二磷酸腺甙(ADP),导致血小板凝集。某些物质如胶原也能引起释放反应,释放出内源性ADP。还有些物质如肾上腺素和外源性ADP,可直接凝集血小板(一期凝集),亦可 Methods to prevent thrombosis in the past mainly hinder the blood clotting, venous thrombosis usually begins in the valve sinus, so the blood flow is relatively slow. Heparin and coumarin prevent this type of thrombosis, but not for arterial thrombosis. Platelet aggregation may be the more important factor that causes arterial thrombosis and thrombosis at the artificial device surface. Experimental and clinical data have increasingly demonstrated that the use of anti-platelet aggregation drug is a new pharmacological approach to prevent thrombosis. Platelets are prone to adhere to certain components of the blood vessel wall after the loss of endometrium, and then release reaction, release of adenosine diphosphate (ADP), resulting in platelet aggregation. Some substances, such as collagen, can also cause a release reaction that releases endogenous ADP. Some substances such as epinephrine and exogenous ADP, can be directly agglutinated platelets (one phase agglutination), but also